EQUITY.GURU podcast - Investing for millennials and madmen
Business:Investing
Welcome to the second installment!
Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval.
Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Listen in!
A Closer Look: 1933 Industries (TGIF.C) focuses on fundamentals in legal cannabis market, who woulda thunk it?
A Closer Look - Rare earth metals miner, Defense Metals (DEFN.V), proving out big numbers at BC property
A Closer Look with Gaalen Engen: Azincourt Energy (AAZ.V) turning Athabasca uranium project into gold
A Closer Look with Ethan Reyes: CannaVerde Pharma positions to capitalize on Colombia's legal cannabis market
A Closer Look: 3D Sustainable Developments is building the world of tomorrow
A Closer Look with Ethan Reyes: ThinkMyco pushes the button on magic mushroom market
Equity.Guru podcast: Andrea Dobbs - a Vancouver rec weed-seller spills the beans
Equity.Guru podcast: Experion Holdings (EXP.V) and the art of executive accountability
Equity.Guru podcast: New Wave Esports maps the future of Esports
Equity.Guru podcast: CopperBank Resources (CBK.V) - a call option on copper that never expires
Equity.Guru podcast: Eureka 93 (ERKA.C) provides answers on dissolved partnerships and 15:1 share rollback
Equity.Guru podcast: Ampd Technologies' high computing solutions revolutionizing the cloud
Equity.Guru Podcast: Fake news in the age of cannabis – featuring Khiron Life Sciences (KHRN.V)
Equity.Guru podcast: Blockchain Foundry (BCFN.C) and the future of cryptocurrency
Equity.Guru podcast: 1933 Industries (TGIF.C) expands to service massive CBD health and wellness market
Equity.Guru podcast: Mag One (MDD.C) and the subtle art of giving a f*ck about the environment
Equity.Guru podcast: Blissco's blissful part in the success of Supreme Cannabis (FIRE.T)
Equity.Guru podcast: It is as it ever was - The Vancouver Island gold rush that helped build B.C.
Equity.Guru podcast: Weekly Crypto Countdown July 12, 2019
Equity.Guru podcast: ProMis Neurosciences (PMN.T) and the fight against Alzheimer's
Join Podbean Ads Marketplace and connect with engaged listeners.
Advertise Today
Create your
podcast in
minutes
It is Free
Get Creative with Pace Morby
U.S Property Podcast
Aligned Money Show
The Ramsey Show
The Clark Howard Podcast